

Performance Against Initiation Benchmark

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
16/WM/0276	207822	Safety of Nasal Influenza Immunisation in Children with Asthma: The SNIFFLE 4 study	08/07/2016	05/10/2016	22/08/2016	05/10/2016	11/10/2016	13/10/2016	20/10/2016	Benchmark Met
16/WM/0359	211812	Blinatumomab in Aggressive B-Cell Non Hodgkin Lymphoma	24/08/2016	27/10/2016	12/10/2016	03/11/2016	03/11/2016	23/11/2016	10/04/2017	Neither
16/EE/0243	207331	A 6 Month Multicentre Phase 3, Open-Label extension Safety Study of OTO-104	22/08/2016	10/10/2016	01/08/2016	16/11/2016	17/11/2016	24/01/2017	26/01/2017	Sponsor
16/SC/0161	186322	GO29438 Phase III Study - Atezolizumab with chemotherapy in Stage IV Non-Squamous	23/09/2016	16/11/2016	12/05/2016	01/12/2016	01/12/2016	05/12/2016	22/12/2016	Benchmark Met
16/SC/0542	208245	OMASPECT	04/11/2016	25/11/2016	09/11/2016	29/11/2016	19/12/2016	19/12/2016	13/01/2017	Benchmark Met
16/EM/0408	211983	A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined with Nivolumab versus Nivolumab Alone in Subjects with Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma	18/10/2016	05/12/2016	02/12/2016	22/12/2016	23/12/2016	29/12/2016	08/02/2017	Benchmark Met
16/EE/0452	209722	A study to evaluate the acceptability of ZestiVits;	06/09/2016	01/11/2016	09/11/2016	02/11/2016	17/11/2016	17/02/2017	10/04/2017	Neither
16/WA/0159	162019	EMPHIS	20/01/2015	05/12/2016	05/12/2016	05/12/2016	06/12/2016	06/12/2016		Sponsor
16/SC/0416	210405	Safety and Efficacy of MEDI8897 Against RSV in Healthy Preterm Infants	26/08/2016	13/10/2016	30/09/2016	24/10/2016	28/10/2016	17/11/2016	14/12/2016	Benchmark Met
16/SW/0201	205118	OPHT 5713	01/07/2016	06/12/2016	19/10/2016	25/11/2016	05/01/2017	27/01/2017	28/03/2017	Neither
16/SC/0530	213306	Ketocal 2.5:1 LQ tolerance trial	17/10/2016	15/12/2016	05/12/2016	03/01/2017	09/01/2017	11/01/2017	30/05/2017	Neither
16/LO/1612	201997	Follow-up Study for Patients who Completed Study ALX0681-C301	10/08/2016	14/10/2016	16/11/2016	09/01/2017	11/01/2017	19/01/2017	24/01/2017	Both
16/SC/0277	202191	Point Of Care Testing For Sepsis: A Diagnostic Accuracy Study	04/10/2016	12/01/2017	18/10/2016	04/10/2016	12/01/2017	03/02/2017	16/03/2017	Benchmark Met
16/SC/0350	199995	Does a ketogenic diet reduce delirium in Intensive Care. Part I - A feasibility study to test if a ketogenic diet causes ketosis in patients on Intensive Care.	04/02/2016	20/02/2017	20/02/2017	20/02/2017	21/02/2017	01/04/2017	17/06/2017	NHS Provider
16/EE/0463	214371	CompLEEment-1	08/08/2016	20/01/2017	30/01/2017	30/01/2017	21/02/2017	15/03/2017	30/03/2017	Benchmark Met
16/LO/1960	199019	Dose finding study of Sarilumab in children with sJIA	08/11/2016	19/12/2016	28/02/2017	24/01/2017	01/03/2017			Sponsor
17/LO/0017	213632	Open-label Extension Study for Participants with Prostate Cancer	05/08/2016	15/02/2017	08/03/2017	09/03/2017	13/03/2017	15/06/2017	11/07/2017	Sponsor
16/LO/1322	208946	RSV-M-301	31/08/2016	28/03/2017	09/09/2016	05/04/2017	06/04/2017	08/05/2017	27/06/2017	Sponsor
16/EM/0512	215840	TRILOGY	06/01/2017	04/04/2017	28/02/2017	05/04/2017	20/04/2017	21/04/2017	02/05/2017	Benchmark Met
16/WS/0197	186191	ATLANTIS	23/03/2017	23/03/2017	01/02/2017	13/04/2017	21/04/2017	28/06/2017	05/09/2017	NHS Provider
16/EE/0421	209972	Athena	02/09/2016	10/03/2017	13/01/2017	23/01/2017	27/04/2017			Sponsor
16/EE/0325	204922	Venetoclax (ABT-199) in relapsed/refractory CLL (M15-550)	14/09/2016	06/03/2017	28/09/2016	02/05/2017	04/05/2017	10/05/2017	23/05/2017	Sponsor
16/NW/0517	188554	Myeloma XII (ACCoRd trial) Version 1.0	01/11/2016	09/05/2017	27/10/2016	12/05/2017	22/05/2017	22/05/2017		Neither
16/NE/0142	202233	CANC 5578 (B9991010)	05/05/2017	05/05/2017	01/11/2016	10/05/2017	23/05/2017	25/05/2017	25/09/2017	NHS Provider

Performance Against Initiation Benchmark

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
17/SC/0055	219468	AIN457 Paed	18/05/2017	22/05/2017	21/03/2017	22/05/2017	23/05/2017	30/05/2017	01/06/2017	Benchmark Met
17/EE/0079	220827	Avacopan in patients with Vasculitis	25/01/2017	20/04/2017	06/04/2017	19/06/2017	22/06/2017	30/06/2017		Sponsor
16/YH/0157	204585	PLATO - Personalising Anal cancer radioTherapy dose	08/06/2017	08/06/2017	20/07/2016	13/06/2017	23/06/2017	26/06/2017	04/07/2017	Benchmark Met
16/ss/0014	187949	GEM3	18/05/2017	14/06/2017	14/10/2016	30/06/2017	30/06/2017	14/09/2017		Sponsor
17/LO/0035	218519	ACTiF - RCT and parallel process evaluation (WP 3.2 and 3.3)	06/01/2017	16/05/2017	03/04/2017	16/05/2017	20/07/2017	18/09/2017		Sponsor
17/SW/0127	225959	Flight-A multicentre randomised trial of First Line treatment pathways for newly diagnosed Immune Thrombocytopenia: Standard steroid treatment versus combined steroid and mycophenolate	15/05/2017	19/06/2017	03/07/2017	19/06/2017	19/06/2017			Sponsor
16/LO/1222	191705	ATLANTIS Trial	17/10/2016	12/05/2017	05/05/2017	13/07/2017	17/07/2017	11/08/2017		Both
17/EM/0063	213979	Gilteritinib as Maintenance After Induction/Consolidation in CR1 AML	12/01/2016	19/04/2017	27/04/2017	31/08/2017	31/08/2017	08/09/2017		Sponsor
16/NE/0325	199217	ECUSTEC trial	16/09/2016	05/06/2017	30/05/2017	13/07/2017	14/07/2017	02/08/2017	21/09/2017	Neither
17/NE/0117	222778	Osteogenesis Imperfecta 3082/0003 Mereo BioPharma	20/01/2017	22/06/2017	25/08/2017	11/07/2017	18/07/2017			Sponsor
17/SC/0142	215503	The 65 Trial (v1.0)	20/03/2017	07/07/2017	24/04/2017	11/07/2017	17/07/2017	31/07/2017	08/09/2017	Benchmark Met
16/YH/0452	130824	VINILO trial	16/08/2016	04/05/2017	09/12/2016	09/05/2017	09/05/2017	10/05/2017	03/07/2017	Benchmark Met
17/NW/0022	219189	Post-Authorization Study of HyQvia in Pediatric PIDD subjects	09/01/2017	27/06/2017	06/03/2017	27/07/2017	27/07/2017	08/08/2017	14/08/2017	Benchmark Met
17/SC/0083	218035	CV185362 Pediatric Anticoagulation for Prevention of Thromboembolism	03/02/2017	10/04/2017	07/07/2017	13/07/2017	27/07/2017	23/08/2017	20/09/2017	Sponsor
17/SC/0039	220282	MAGPIE	03/05/2017	05/07/2017	18/04/2017	07/07/2017	11/07/2017	07/08/2017	14/08/2017	Benchmark Met
16/LO/2141	200571	Biomede	06/06/2017	07/07/2017	06/04/2017	07/07/2017	07/07/2017	12/07/2017	27/07/2017	Benchmark Met
16/NW/0629	211995	CF START	15/08/2017	08/09/2017	22/09/2016					70 days not yet reached
17/NW/0223	219119	Evaluation of PKU explore	08/08/2017	07/09/2017	22/04/2017	14/09/2017	14/09/2017	29/09/2017		Benchmark Met
17/EM/0075	222172	High Energy, High Protein Tube Feed Study	27/02/2017	27/03/2017	27/03/2017	09/05/2017	11/05/2017	15/05/2017	26/05/2017	Benchmark Met
16/ES/0110	207747	TOPaZ study	13/01/2017	13/01/2017	12/01/2017	01/03/2017				Sponsor
16/LO/1457	199790	HEPA 5188	01/02/2017	16/05/2017	12/10/2016	21/06/2017	19/09/2017	21/09/2017		NHS Provider
16/EM/0194	194984	DERM 5311	24/08/2016	06/06/2017	24/06/2016	12/06/2017	12/06/2017	03/07/2017	03/08/2017	Benchmark Met
15/EM/0455	183600	SEL-I-METRY	22/08/2017	22/08/2017	15/06/2016	26/09/2017				70 days not yet reached
16/NE/0316	207651	Phase 1 Study CYP-001 for the Treatment of Acute Graft vs Host Disease	11/01/2017	28/02/2017	12/12/2016	06/05/2017	09/05/2017	09/05/2017	10/05/2017	Sponsor
17/EM/0152	216307	Post-transplant Gilteritinib maintenance in acute myeloid leukaemia	19/10/2016	15/09/2017	21/07/2017					70 days not yet reached
17/LO/0038	182633	UK P3BEP Trial	22/05/2017	22/09/2017	06/04/2017					70 days not yet reached
16/YH/0450	213782	20150288 - Blinatumomab in DLBCL	06/02/2017	10/03/2017	25/01/2017	12/07/2017	18/07/2017	25/07/2017		Sponsor
16/WS/0089	197457	PARADIGM-2	09/06/2017	27/07/2017	16/12/2016	02/08/2017	15/08/2017	31/08/2017	11/09/2017	Benchmark Met

Performance Against Initiation Benchmark

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
17/LO/0023	215490	MUK nine b: OPTIMUM	12/01/2017	30/08/2017	30/03/2017					70 days not yet reached
17/LO/0249	220398	CO39385: Study of Atezolizumab + Enzalutamide vs Enzalutamide in mCRPC	16/06/2017	13/07/2017	28/04/2017	10/08/2017	22/08/2017			Sponsor
17/SC/0228	219158	Javelin Head and Neck	16/12/2016	02/08/2017	24/07/2017					70 days not yet reached
16/WS/0165	190574	ADSCaN.	19/07/2017	02/08/2017	13/02/2017	31/08/2017	28/09/2017			70 days not yet reached
17/WA/0087	222840	The Caravaggio Study	26/06/2017	14/09/2017	06/07/2017					70 days not yet reached
17/LO/0731	219463	PIVOTALboost	12/09/2017	12/09/2017	27/07/2017					70 days not yet reached
17/LO/1174	229691	Phase 2 of Filgotinib in patients with active non-infectious uveitis	19/06/2017	27/09/2017	22/08/2017					70 days not yet reached
16/LO/0058	193773	LAVA- Liver resection surgery versus thermal ablation for CLM	11/07/2017	04/09/2017	22/08/2016	12/09/2017	29/09/2017			70 days not yet reached